ALS Association: The Lawrence and Isabel Barnett Drug Development Program (LOI)

Topics of interest:

Both novel programs and repurposing of approved or clinically safe therapies from other disease indications are appropriate for this funding opportunity.

Especially interested in: • In vivo efficacy testing of therapeutic candidates (pharmacological treatments, biological therapies, or gene therapies) in models of ALS. • Studies focused on pharmacokinetics, pharmacodynamics, preclinical toxicology/safety (ADME/Tox), dose-range finding, and target engagement. • Other Investigational New Drug (IND)-enabling studies.

Funding: $500,000 in total funding over 2 years

https://www.als.org/research/funding-opportunities

https://www.als.org/sites/default/files/2023-11/2024-Barnett-RFA.pdf